Progress of immune checkpoint inhibitors in gastric cancer

Table 2 Clinical trials of programmed death 1 for gastric cancer

Immune checkpoint inhibitor	Patient	Method	Phase	Ref.
Pembrolizumab	Recurrent or metastatic PD-L1-positive GC/GEJ	Intravenously once/2 weeks in 2 years or until progression or unbearable toxic reactions	Ib	Muro et al[37]
Pembrolizumab	Previously treated GC/GEJ	Intravenously once/3 weeks until progression, or unbearable toxic reactions	Ⅱ	Fuchs et al[38]
Pembrolizumab	Advanced GC/GEJ with poor outcomes after chemotherapy	Once/3 weeks for 24 months	III	Shitara et al[39]
Pembrolizumab	Untreated, advanced GC/GEJ with positive score (CPS) ≥ 1	Once/3 weeks	Ⅲ	Shitara et al[40]
Camrelizumab (SHR1210)	Recurrent, metastatic refractory or intolerant GC/GEJ after previous chemotherapy	Intravenously once and 4 weeks later once/2 weeks	I	Huang et al[41]
Pembrolizumab	Advanced PD-L1-positive GC/GEJ (CPS ≥ 1)	Intravenously once/3 weeks for 2 years	I	Chung et al[42]
Toripalimab	Advanced chemo-refractory GC patients	Monotherapy with Toripalimab (3 mg/kg, every 2 weeks)	Ib/II	Wang et al[43]
Nivolumab	Locally advanced or metastatic chemotherapy-refractory GC	Intravenously once/2 weeks	I/II	Janjigian et al[44]
Nivolumab	Advanced GC/GEJ, previously treated with chemotherapy	Intravenously once/2 weeks until progression or unbearable toxic reactions	Ⅲ	Kang et al[45]

CPS: Combined positive score; GC: Gastric cancer; GC/GEJ: Gastric cancer/gastroesophageal junction; PD-L1: Programmed death ligand 1.